

Establishing the Foundation for Nonclinical Entry of VLP-Peptide-Based Pancreatic Cancer Immunotherapy Vaccine Candidate

POSVAX Co., LTD.



ONCOLOGY	Candidate
Product Type	rProtein
Indication	Pancreatic cancer
Target	hTERT
MoA(Mechanism of Action)	Eliminating pancreatic cancer cells by administering a highly immunogenic vaccine loaded with hTERT T-cell epitopes
Competitiveness	hTERT is well known as an antigen specifically expressed in pancreatic cancer. To induce a robust immune response against the T-cell epitope of hTERT, virus-like particles (VLPs) were applied as a delivery vehicle for this epitope. This strategy is expected to effectively induce pancreatic cancer-specific CTL responses.
Development Stage	Candidate
Route of Administration	I.M.

Any unauthorized distribution or reproduction of this material is strictly prohibited.